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ABSTRACT 
 
Langni Liu, M.S. Department of Pharmacology and Toxicology, Wright State 
University, 2013. Endothelial Cell Derived MVs and Exosomes: Release and 
Functional Study. 
 
 
 
Extracellular vesicles are membrane derived vesicles exists in all organs. The 
two major functioning extracellular vesicles are exosomes (EXMs) and 
microvesicles (MVs). EXMs released from cell membranes via exocytosis with 
size between 30-150 nm in diameter and MVs directly budded from plasma 
membrane and size between 100-1000 nm. Ceramide is one of the most 
important factor in lipid mechanism for EXM release and also associated with 
MV release. Ceramide generated from breakdown of sphingomyelin by neutral 
sphingomyelinase (nSMase). In this study, we used an nSMase inhibitor 
(GW4869) and an analogue of ceramide (C6-ceramide) to modulate the release 
of MVs and EXMs in human brain microvascular endothelial cells (ECs), and to 
test the effects of these modulations on EC proliferation, microRNA126 (miR-
126) expression and MV uptake ability and the interaction between EC derived 
MVs/EXMs (EC-MVs/EXMs) with target cell, human brain smooth muscle cells 
(SMCs). Endothelial cells were treated with GW4869 in 10 µM and C6-ceramide 
in 10 µM for 24 h. MVs were isolated from by centrifuge and EXMs were isolated 
by centrifuge at 20,000 x g for 2 h and EXM were isolated by ultracentrifuge at 
120,000 for 2 h with 100 nm filtration. MVs and EXMs size and concentration 
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were analyzed by Nanoparticle Tracking Analysis (NTA) technique. Cell 
proliferation was detected by MTT. The levels of miRNA126 expression in ECs 
and EC-MVS/EXMs were detected by qRT-PCR. MV uptake measured by 
fluorescent microscope. Migration measured by wound healing method. 
GW4869 significantly decreased EXM release and C6-ceramide significantly 
increased both MV and EXM release in ECs. ECs treated with C6-ceramide 
and GW4869 had different miR-126 expression and MV uptake ability. 
Modulated EC-MVs/EXMs had no effect on normal SMC proliferation and 
migration, but EC-EXMs under both release regulation decreased angiotensin 
II (Ang II) induced SMC migration independent of miR-126 level in EXMs. Our 
data demonstrate that modulation of MV/EXM via C6-ceramide and GW4869 
could affects EC function and it`s derived MVs/EXMs function, which may imply 
in vascular physiology and pathology. 
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INTRODUCTION 
 
Endothelial cells 
Endothelial cells (ECs), the main cell components of blood vessels, form a thin 
monolayer lining in the interior vessel surface which acts as an anticoagulant 
barrier between the vessel wall and blood. This thin layer of ECs, also defined 
as endothelium, plays an important role in maintaining normal vascular 
structure and function. 
 
As early as the 1850s, the structure and function of the endothelium were first 
being explored by Ludwig. However, scientists in that period more likely 
believed that the endothelium works as an inert semipermeable barrier that only 
controls the exchange of substrates between blood vessels and tissues. At the 
beginning  of 1953, a series of studies of ultrastructure and physiology finally 
led to the idea that the endothelium is a dynamic, heterogeneous, disseminated 
organ that possesses vital secretory, synthetic, metabolic, and immunologic 
functions [1]. 
 
Endothelial function  
ECs regulate various physiological functions, such as blood fluidity, vascular 
tone, platelet adherence, cell proliferation, vascular inflammation and the 
balance between coagulation and fibrinolysis (Table 1).    
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Under normal conditions, the endothelium releases a variety of relaxing and 
contracting factors to regulate vascular tone.  Stimuli such as thrombin, 
bradykinin or increasing shear stress will release EC nitric oxide (NO). NO is 
produced from L-arginine by a functional endothelial NO synthase (eNOS) [2]. 
NO is also  known as endothelium-derived relaxing factor (EDRF) [3]. NO 
activates the enzyme guanylate cyclase in vascular smooth muscle cells, thus 
resulting in cyclic GMP increase  and causing vasorelaxation [3]. ECs can also 
mediate hyperpolarization of vascular smooth muscle cells via endothelium-
derived hyperpolarizing factors (EDHF), an NO-independent pathway, which 
increases potassium conductance and subsequent propagation of 
depolarization of vascular smooth muscle cells [4]. Of note, the basal tone is 
also modulated by vasoconstrictors such as endothelin-1 (ET-1), reactive 
oxygen species (ROS), endothelin, angiotensin II (Ang II) and prostacyclin [5, 
6]. 
  
ECs also play important roles in immune and inflammatory reactions via 
regulating lymphocytes and leukocytes. Lymphocytes can interact with ECs 
under normal homeostasis condition by the L-selectin receptor. Lymphocyte 
activation up-regulates the expression of leukocyte function-associated 
antigen-1 (LFA-1) and very late antigen-4 (VLA-4), which promote lymphocyte-
EC adhesion via interacting with pro-inflammatory factors such as EC adhesion 
molecules, Intercellular adhesion molecules 1 and 2 (ICAM-1 and ICAM-2), and 
vascular cell adhesion molecule (VCAM). Under normal conditions, there is little 
to no expression of pro-inflammatory factors. During inflammation processes, 
leukocyte adhesion is increased and ECs are activated [7]. NO has been shown 
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to inhibit leukocyte adhesion [8]. The activation of ECs promotes the generation 
of a variety of cytokines including interleukins, tumor necrosis factor and cell 
adhesion molecules. The inflammatory cytokines produced by ECs activate 
nuclear factor-kappa beta (NF-κβ) and up-regulate EC adhesion molecules, 
which direct the process of inflammation [9]. As the barrier that is in direct 
contact with blood, the endothelium controls blood fluidity and coagulation 
through the factors that regulate the clotting cascade, platelet activity, and the 
fibrinolytic system [9]. 
 
Endothelial function Associated regulator 
Maintenance of vascular tone NO, PGI2, TxA2, EDHF, E-1, Ang II 
Balancing blood fluidity and 
thrombosis 
NO, t-PA, PAI-1, TF, PGI2, TxA2, 
vWF, fibrinogen, thrombomodulin, 
heparin 
Control of the vascular 
inflammatory process 
VCAMs and ICAMs, NF-κβ, MCP-1, 
P and E selectin, IL-1, IL-6, IL-18, 
TNF 
Vasculogenesis/angiogenesis VEGF, PDGF, TGF-β 
 
Table 1. Endothelial functions and function associated regulators. Ang II: 
Angiotensin II; EDHF: Endothelium-derived hyperpolarizing factor; ET-1: 
Endothelin-1; ICAM: Intercellular adhesion molecule; IL: Interleukin; MCP-1: 
Monocyte chemotactic factor-1; NF-κβ: Nuclear factor kappa beta; NO: Nitric 
oxide; PAI-1: Plasminogen activator inhibitor-1; PDGF: Platelet-derived growth 
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factor; PGI2: Prostacyclin; TF: Tissue factor; TGF-β: Transforming growth 
factor-beta; TNF: Tumor necrosis factor; t-PA: Tissue plasminogen activator; 
TxA2: Thromboxane A2; VCAM: Vascular cellular adhesion molecule; VEGF: 
Vascular endothelial growth factor; vWF: von Willebrand’s factor. 
 
Endothelial Dysfunction 
Endothelial dysfunction refers to abnormalities in the phenotype and functions 
of endothelial cells. It causes reduced anti-inflammatory properties and 
prothrombic properties of the endothelium, impaired modulation of vascular 
growth, dysregulation of vascular remodeling and an imbalance in the 
endothelium-derived relaxing and contracting factors (Fig 1). 
 
 
 
Fig 1. Consequences of endothelial dysfunction. 
 
 
 
 
Endothelial Dysfunction 
Vascular lesion 
and remodeling Inflammation Vasoconstriction Thrombosis 
Plaque 
rupture 
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The loss of NO bioactivity is defined as the hallmark of endothelial dysfunction. 
NO maintains the vascular wall in a quiescent state by targeting several 
regulators such as NF-κβ to silence the cellular inflammatory process. The 
decline in NO bioavailability causes EC dysfunction. NO reduction may be 
caused by decreased expression of eNOS or eNOS activity (a lack of substrate 
or cofactors) or accelerated NO degradation by reactive oxygen species (ROS) 
[10]. 
 
Oxidative stress appears to play a pivotal role in the alteration of endothelial 
function. Oxidative stress increases vascular endothelial permeability and 
promotes leukocyte adhesion, which is coupled with alterations in endothelial 
signal transduction and redox-regulated transcription factors such as NF-κβ [11]. 
It is also increasingly recognized that cell differentiation and proliferation, 
cytokine expression, and programmed cell death are determined by oxidation-
sensitive regulatory pathways [12]. 
 
Cardiovascular disease risk factors initiate a chronic inflammatory process that 
is accompanied by a loss of vasodilators and anti-thrombotic factors and an 
increase in vasoconstrictors and pro-thrombotic products. Mostly, risk factors 
as diverse as smoking, aging, hypercholesterolemia, hypertension, 
hyperglycemia, and a family history of premature atherosclerotic disease, 
obesity, elevated C-reactive protein, and chronic systemic infection are all 
associated with endothelial dysfunction [9]. 
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Extracellular vesicles 
Extracellular vesicles, also called microparticles, are membrane-derived 
vesicles that can be released from almost all cells. They carry various DNAs, 
proteins, mRNAs, and microRNAs (miRNAs) that have potential diagnostic and 
therapeutic purposes. Extracellular vesicles can transfer molecular contents to 
recipient cells. This ability to carry and transfer biological information makes 
extracellular vesicles an important way of intercellular communications and 
could service as biomarkers. 
 
Extracellular vesicles are mainly characterized into 3 categories: 1) exosomes 
(EXMs); 2) microvesicles (MVs); and 3) apoptotic bodies. EXMs and MVs are 
the functional extracellular vesicles. Even though both EXMs and MVs are 
released from cellular membranes, the differences in their biogenesis and 
parental cells provide them with function differences. 
 
Key features of EXMs and MVs 
Exosomes are vesicles surrounded by a phospholipid bilayer and their size is 
approximately 30–150 nm in diameter. Endocytic vesicles bud into early 
endosomes and multi-vesicular body (MVB) as form of intraluminal vesicles 
(ILVs). MVBs either fuse with lysosomes or fuse with the plasma membrane. 
Fusion with the plasma membrane allows them to release their content, which 
are exosomes [13]. EXMs feature phosphatidylserine (PS) on the outer 
membrane leaflet and exosomal markers such as CD63 and CD9 [14]. The 
widely accepted protocol for EXM isolation includes ultracentrifugation, 
sometimes in combination with sucrose density gradients or sucrose cushions 
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to float the relatively low-density exosomes [15]. Flow cytometry is a popular 
tool to detect extracellular vesicles. It is more commonly used in detection of 
MVs because of its limitation in detected particle size. Nanoparticle tracking 
analysis (NTA) technique is a new technique to track the size and distribution 
of small particles. The ability of NTA for tracking small particles makes it the 
more sensitive and accurate method for tracking EXMs, compared to flow 
cytometry. 
 
MVs are structures surrounded by a phospholipid bilayer and their size is 
approximately 100–1000 nm in diameter. MVs are released from cells by 
directly budding from membranes. MVs have bound PS on the outer membrane 
leaflet. Several studies also consider that MVs lack PS externalization due to 
the inability of PS to bind to annexin V [16]. One of the main isolation methods 
of MVs is by centrifugation. The methods of detection for MVs are the same as 
EXMs. 
 
Functions of MVs and EXMs 
MVs and EXMs can directly or indirectly control a variety of biological processes 
by transferring membrane proteins, signaling molecules, mRNAs, and miRNAs 
and activate receptors in recipient cells. I Interaction of extracellular vesicles 
with other cells occurs in various physiological and pathological processes, 
including inflammation, cancer, infectious diseases and neurodegenerative 
disorders. 
 
MVs and EXMs derived from different parental cells have their respective 
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functions. Several studies have indicated that extracellular vesicles participate 
in the development and progression of atherosclerosis. Atherosclerotic plaques 
contain large amounts of extracellular particles. The variety of factors 
expressed in plaques vesicles stimulate T lymphocytes that might causes B 
lymphocytes activation and production of specific immunoglobulins which have 
the ability to against atherosclerotic plaque antigens or apoptotic cell debris [17, 
18].  
 
MVs and EXMs also have pro- or antiangiogenic activities, depending on their 
cellular origin. Several studies indicated that angiogenesis is enhanced by MVs 
or EXMs released by endothelial cells and platelets [19, 20]. EXMs derived from 
CD34+ hematopoietic stem cells contribute to hypoxia-induced angiogenesis 
[21]. Cancer cell derived MVs and EXMs favor angiogenesis by promote 
endothelial cell proliferation, migration, tube formation and vascular leakiness 
[22].  
 
MV and EXM releasing mechanism 
The releasing mechanism of EXMs can be mainly described as two parts: The 
endosomal sorting complex required for transport (ESCRT) mechanism and 
ESCRT-independent mechanism. 
 
The ESCRT consists of four complexes: ESCRT-0 is responsible for cargo 
clustering in an ubiquitin-dependent manner, ESCRT-I and ESCRT-II 
responsible for promoting bud formation, ESCRT-III drives vesicle scission [13]. 
Members of the ESCRT family had been proved shown in a variety of cells and 
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control EXM release. Inhibition of HRS, an ESCRT-0 member, decreased 
exosome secretion [23]. Depletion of TSG 101, an ESCORT-1 member, 
decreased exosome in tumor cells [13, 24]. ALIX-syntenin, which belongs to 
the ESCRT-III complex induced intraluminal budding of vesicles in endosomes, 
which regulates exosome formation and secretion [25].    
 
Besides ESCRT mechanism, several studies suggested that ESCRT-
independent mechanisms are also involved in ILV formation and EXM 
biogenesis. These mechanisms involve lipids (including ceramide), 
tetraspanins, or heat shock proteins [13]. Ceramide, one of the most important 
factors of the lipid ESCRT-independent mechanism has been shown to regulate 
exosome formation and release in several cells [25, 26]. Ceramide is a central 
second messenger that has been shown to cause cell growth arrest and 
apoptosis. It is generated from the breakdown of sphingomyelin (SM) by neutral 
sphingomyelinase (nSMase) [27]. Inhibition of nSMase reduces ceramide 
generation and causes decrease in EXM release. As the analog of ceramide, 
the exogenous C6-ceramide increases the EXM release via this lipid 
mechanism (Fig 2). 
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Fig 2. Simple diagram of the nSMase-ceramide mechanism regulating 
exosome release. SM: sphingomyelin; nSMase: neutral sphingomyelinase; 
 
Endothelial MVs and EXMs  
EC derived MVs (EC-MVs) and EC derived EXMs (EC-EXMs) carry endothelial 
proteins such as platelet endothelial cell adhesion molecule-1, intercellular cell 
adhesion molecule (ICAM)-1, or E-selectin. Several studies showed that EC-
MVs or EC-EXMs provide protective effects to recipient cells. Endothelial 
progenitor cells derived MVs contribute to hypoxia/reoxygenation induced 
endothelial dysfunction and apoptosis via their carried micorRNA126 (miR-126) 
associated with ROS production and the PI3K/eNOS/NO pathway [28]. miR-
126 is highly expressed in endothelial cells. It had been reported to be specific 
for vascular system in zebrafish [29]. In many studies, miR-126 had been 
reported can regulate vascular integrity and angiogenesis [30, 31]. The 
expression of miR-126 in MVs and EXMs proved that MVs and EXMs can 
transfer messages molecules from endothelial cells and affect recipient cells 
functions. 
SM nSMase Ceramide↑ 
Exosome release ↑ 
Inhibitor 
(GW4869) 
Exosome release ↓ 
exocytosis 
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II.  HYPOTHESIS AND SPECIFIC AIMES 
 
Hypothesis:  
It is hypothesized that modulation of microvesicle (MV)/exosome (EXM) release, 
without affecting endothelial cell (EC) proliferation, alters the microRNA 126 
(miR-126) content and function of ECs, and affects the miR-126 content and 
function of EC derived MVs/EXMs on vascular smooth muscle cell (SMC) 
proliferation and migration. 
 
Specific Aims: 
Aim 1: To evaluate the effects of C6-Ceramide and GW4869 on EC MV and 
EXM release. 
 
Aim 2: To determine the impacts of C6-Ceramide and GW4869 on EC 
proliferation, miR-126 expression and MV uptake ability. 
 
Aim 3: To evaluate the effects of EC-MVs/EXMs released under C6-Ceramide 
or GW4869 modulation on SMC proliferation and migration. 
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III.   EXPERIMENTAL DESIGN 
 
Design for Aim 1: 
ECs were cultured and treated with C6-Ceramide at 0, 10, 15 µM or with 
GW4869 at 0, 5, 10 µM for 24 hours. Culture medium samples were collected 
for MV and EXM isolation. Particle size and concentration were analyzed by 
NTA to determine the effective concentration for further experiments. The levels 
of miR-126 in MVs and EXMs were measured by Quantitative real-time PCR 
(qRT-PCR). ECs at passages 8-16 were used in this study. 
 
Design for Aim 2: 
ECs were cultured and treated with C6-Ceramide at 0, 10, 15 µM or with 
GW4869 at 0, 5, 10 µM for 24 hours. Cell proliferation was tested using the 
MTT method. The NTA and cell proliferation results, provided the effective 
concentration for further experiments. ECs were divided into 3 groups: Vehicle; 
C6-Ceramide treatment; GW4869 treatment. Expression of miR-126 in ECs 
was detected by qRT-PCR. MV uptake rates of ECs with different treatment 
groups were analyzed by fluorescence microscopy and image J software. ECs 
at passage 8-16 were used in this study. 
 
Design for Aim 3: 
SMCs were cultured and treated with EC derived MVs or EXMs (10 µg/ml) for 
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24 hours. Cell proliferation was measured by the MTT method and cell 
migration was measured by the wound healing method. SMCs at passage 5-8 
were used in this study. 
 
 
Fig 3. Flow chart of the experimental design in this study. EXMs: exosomes; 
ECs: endothelial cells; SMCs: smooth muscle cells; miR-126: microRNA 126; 
MVs: microvesicles; NTA: nanoparticle tracking analysis.       
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Design for Aim 1 
Design for Aim 3 
Design for Aim 2 
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IV.   MATERIALS AND METHODS 
 
Materials 
Human brain microvascular endothelial cells, CSC complete medium, human 
recombinant growth factors (CSC CultureBoost-R), attachment factor, CSC 
serum free medium and RocketFuel supplements were purchased from Cell 
Systems Corp. (Kirkland, WA, USA). DMEM high glucose medium, L-glutamine, 
Fetal Bovine Serum (FBS), antibiotic-antimycotic solution, trypsin, methyl 
thiazolyl tetrazolium (MTT), TRIzol reagent were purchased from Invitrogen 
(Carlsbad, CA). N-Hexanoyl-D-sphingosine (C6-Ceramide), GW4869, PKH26 
were purchased from Sigma-Aldrich Co. LLC (Saint Louis, MO, USA). 
 
Cell culture and treatment 
Human brain microvascular endothelial cells and human brain microvascular 
smooth muscle cells were used in this study. ECs were cultured in CSC 
complete medium with 10 % FBS, 2 % human recombinant growth factors, 1 % 
L- glutamine and 1 % antibiotic-antimycotic solution in a cell incubator with a 
standard cell culture atmosphere (37 °C, 5 % CO2). Culture medium was 
replaced every 2-3 days. ECs at passage 8-16 were used in this study. For 
passaging, with 85-90 % cell confluence, culture medium was discarded and 
replaced With 0.025 % trypsin/0.01% EDTA at 37 °C for 5-10 min, then added 
DMEM/F12 medium with 10 % FBS to stop the reaction. After centrifuge at 300 
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x g for 5 min, pellet was resuspended with CSC complete medium and passage 
in a 1:3 ratio for further culture.  
 
C6-Ceramide and GW4869 were dissolved in DMSO to 90 mM as stock 
solution and stored in -20 °C.  ECs were mainly divided into 3 groups: Vehicle 
group, cells treated with DMSO as control; +C6-Ceramide group， cells treated 
with C6-ceamide for 24 hours, +GW4869 group, Cells treated with GW4869 for 
24 hours. Before treating with drugs, ECs were cultured with serum free CSC 
medium (supplemented with 1.4 % RocketFuel, 1 % L-glutamine and 1 % 
antibiotic-antimycotic solution) overnight, then replaced with fresh serum free 
CSC medium and treated with C6-Ceramide at 0, 10, 15 µM or GW4869 at 0, 
5, 10 µM for 24 hours. NTA and EC proliferation were analyzed to determine 
the effective concentration for further experiments. From the NTA and cell 
proliferation results, a concentration of 10 µM for C6-Ceramide and GW4869 
was identified as an effective concentration. After treatment with the effective 
concentration for 24 hours, ECs were collected for further experiments, culture 
medium samples were collected for MV and EXM isolation.  
 
SMCs were cultured in DMEM high glucose medium with 10 % FBS, 1 % L-
glutamine and 1 % antibiotic-antimycotic solution in a cell incubator with a 
standard cell culture atmosphere (37 °C, 5 % CO2). Culture medium was 
replaced every 2-3 days. SMCs at passage 5-8 were used in this study. 
 
Cell proliferation assay 
EC proliferation was tested by MTT assay, an easy and rapid colorimetric assay 
16 
 
for assessing cell metabolic activity. In cells, NAD(P)H-dependent cellular 
oxidoreductase enzymes which reflect the number of viable cells present are 
capable of reducing the tetrazolium dye MTT to its insoluble formazan, which 
has a purple color. The differences in the color level showed the different ability 
in cell proliferation [32, 33]. ECs were cultured in 96-well plate. When cells 
reached 85-90 % confluence, the culture medium was replaced with serum free 
CSC medium overnight, then cells were treated with C6-Ceramide at 0, 10, 15 
µM or GW4869 at 0, 5, 10 µM for 24 hours. After that, 20 𝜇L of MTT solution 
(12 mM) were added to each well and ECs were incubated at 37 °C for 4 hours 
in the dark. Afterwards, the cultured medium was discarded, and 150 𝜇L of 
DMSO was added to each well and cells were incubated for 15 min at room 
temperature in the dark. The dye optical absorbance was read at 572 nm. The 
percent of cell proliferation was expressed as the relative optical absorbance of 
treated groups versus the vehicle group [28].   
 
Isolation of EC-MVs and EC-EXMs. 
ECs were cultured with serum-free CSC medium overnight and treated with C6-
Ceramide or GW4869 at 10 𝜇M in serum-free medium for 24 hours. After 
treatment, culture medium samples were collected and spun at 300 x g for 10 
min followed by centrifugation at 2,000 x g for 20 min to remove cells and cell 
debris. The supernatant were then spun at 20,000 x g for 2 hours to pellet EC-
MVs. The MV pellet was resuspended with 1 ml sterile-filtered phosphate 
buffered saline (PBS) (filtered through 0.2 𝜇m filter). The supernatant of the MV 
pellet was collected and spun in an ultracentrifuge at 120,000 x g for 2 hours 
and filtered through a 0.1 µm filter. After ultracentrifugation, the supernatant 
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was removed, and EXM pellet was resuspended with 100 µl sterile-filtered PBS. 
All MV and EXM samples were stored in -80 °C for further use. 
 
Nanoparticle tracking Analysis (NTA) 
The size and concentration of EC-MVs and EC-EXMs were detected by NTA 
using an NS300 instrument (NanoSight, Amesbury, UK). The NTA technique 
can measure the size distribution of vesicles ranging from 50 nm – 1 µm in 
diameter. The threshold of particle concentration detection is between 107 - 109 
particles/ml. For more accurate detection, MV and EXM samples are diluted 
with PBS to a particle concentration of about 108 particles/ml. After dilution, 700 
µl of diluted sample was loaded to the machine for recording particle movement 
videos in a rate of about 30 frames/s. Particle movement videos were recorded 
3 times per test at different positions and particle movements were analyzed by 
the NTA software (version 2.2, NanoSight). The results of NTA were presented 
as the mean of the 3 tests. The final particle concentration was calculated after 
considering the dilution factor of the NTA results. 
 
 
Co-incubation of EVs with ECs and SMCs 
To track the MVs and EXMs uptake of ECs and SMCs, isolated MVs and EXMs 
were added with 2 µl of the PKH26, a lipid-bound red fluorescent dye, for 5 min 
at room temperature in the dark. All the samples were then spun in an 
ultracentrifuge at 120,000 x g for 2 hours and washed with sterile-filtered PBS 
once. The pellets were resuspended with sterile-filtered PBS as PKH26 labeled 
MVs and EXMs. The PKH26 labeled MVs or EXMs were added to ECs or SMCs 
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at 10 µg/ml and incubated for 24 hours. Fluorescence images were taken by a 
fluorescence microscope to determine the communication of MVs and EXMs 
with ECs and SMCs. 
 
 
MV uptake measurement 
ECs were incubated in 12-well plate with CSC complete medium. Cells  at 85-
90 % confluence were cultured with CSC serum-free medium overnight then 
cultured with PKH26 labeled EC derived MVs at 10 µg/ml for 24 hours. Both 
cell images and fluorescence images were taken by the Essen IncuCyte ZOOM 
instrument (Essen BioScience) every 3 hours within 24 hours. The intensity of 
red fluorescent particles were analyzed by the NTA machine.  
  
Gene expression analysis for miR-126 
miR-126 from treated ECs, EC-MVs, and EC-EXMs was extracted by using the 
TRIzol reagent. ECs were cultured in T-75 flasks. After treatment, the culture 
medium was removed and the cells were dissolved in 1 ml TRIzol reagent and 
collected into 1.5 ml microcentrifuge tubes. Afetrwards, 200 µl chloroform was 
added to each tube and shaken for 15 sec. The tubes were left for 10 min at 
room temperature and then spun at 12,000 x g for 15 min at 4 °C. After 
centrifugation, the samples were separated in 3 layers with the upper clear layer 
containing the RNA extracted from the samples. The middle white cloudy 
interphase contains DNA. The upper layer was transferred to a new tube 
avoiding contamination with the second layer. Pre-cooled isopropanol (500 µl) 
was added to the RNA-containing sample, mixed by pipetting up and down. 
19 
 
After 5-10 min at room temperature, samples were spun at 1,200 x g for 10 min 
at 4 °C. The supernatant was discarded and the pellet suspended with 1 ml 75 % 
ethanol. Samples were spun once more at 7,500 x g for 5 min at 4 °C and the 
supernatant discarded. Afterwards, all the tubes were left at room temperature 
until the ethanol had evaporated, the RNA was dissolved in RNase-free water 
for later processing. cDNA was synthesized using the Prime Script reverse 
transcription Reagent kit (QIAGEN) following the manufacturer’s instructions. 
qRT-PCR was conducted with miR-126 specific primers and miScript SYBR 
Green PCR Kit (QIAGEN) on a real-time PCR system (Bio-Rad). Small nuclear 
RNA U6 (U6) was used as an internal control. Relative expression of miR-126 
was calculated using the 2−ΔΔ CT method [28]. 
 
Cell migration assay 
SMC migration was determined in 12-well plates using the wound healing 
methods described previously with small modifications [34]. Briefly, 80 to 90% 
confluent SMCs were used in this study. Cells cultured in plates were scraped 
with a sterile pipette tip across the diameter of each well to produce wounds 
about 1 to 1.5 mm wide. Then cells were rinsed once to remove cellular debris 
and replaced with fresh serum-free DMEM high glucose medium. Images were 
taken at the initial time of wounding (0 h) using an inverted fluorescence 
microscope. Cells were then treated with EC-MVs and EC-EXMs in the 
presence and absence of Angiotensin II (Ang II, 100 nM). Images were taken 
every 3 hours at 3 different positions per well. Images were analyzed by Image 
J software. Data are presented as the fold changes of the differences in the 
wounded area at 0 and 24 hours.  
20 
 
 
Statistical analysis 
All results were presented as means ± SEM of at least three experiments. 
Student t-test was used to compare significant differences between two groups. 
Multiple comparisons were analyzed by one or two-way ANOVA. A value of 
P<0.5 was considered statistically significantly different. All statistical analyses 
were performed using GraphPad Prism 6.01 software.
21 
V. RESULTS 
 
C6-Ceramide increased both EC-MV and EC-EXM release, whereas, 
GW4869 only decreased EC-EXM release at 10 µM. 
Cultured ECs were treated with the MV/EXM releasing regulator C6-Ceramide 
at 0, 10, 15 µM or with GW4869 at 0, 5, 10 µM for 24 hours. Total particles 
including MVs and EXMs were collected from the culture medium. The NTA 
results showed that GW4869 significantly reduced particle release at 10 µM 
and C6-Ceramide significantly induced particle release starting at 10 and 15 
µM compared to the control (Fig 4A). At 15 µM, C6-Ceramide did not show 
significant changes in inducing particle release compared to the treatment at 
10 µM. Based on these results, the concentration of 10 µM for both C6-
Ceramide and GW4869 was considered as an effective concentration for 
MV/EXM release for further experiments. To confirm the effectiveness of this 
concentration, MVs and EXMs were isolated separatedly from the culture 
medium of C6-ceramide/GW4869 treated ECs by ultracentrifugation. As shown 
in Figure 3, C6-Ceramide significantly induced both MV and EXM release (~1.5 
fold). GW4869 significantly reduced EXM release but had no significant effect 
on MV release.  
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A) 
 
B)  
 
Fig4. C6-Ceramide / GW4869 modulates MV/EXM release in ECs. A) NTA 
results showing that C6-Ceramide or GW4869 modulates particle concentration 
in ECs at different concentrations. ECs were treated with C6-ceramide at 0, 10, 
15 µM or GW4869 at 0, 5, 10 µM for 24 hours. The total particle concentration 
in culture medium was analyzed by NTA. B) Data summary of NTA represents 
MVs/EXMs concentration changes as fold change of control after MV/EXM 
release regulation. ECs were treated with C6-ceramide or GW4869 at 10 µM 
* 
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23 
for 24 hours. MVs and EXMs were isolated from cell culture medium by 
centrifugation and ultracentrifugation methods. Size and concentration of MVs 
and EXMs were measured by NTA. Data are presented as mean ± SEM, 
n=4/group, * P<0.05 versus Veh. Veh: Vehicle group; MVs: EC derived 
microvesicles; EXMs: EC derived exosomes; NTA: nanoparticle tracking 
analysis. 
 
Both C6-Ceramide and GW4869 had no effect on EC cell proliferation at 
10 µM. 
Similarly to the previous treatment steps, cultured ECs were treated with C6-
Ceramide at 0, 10, 15 µM or GW4869 at 0, 5, 10 µM for 24 hours. As shown in 
figure 5, C6-Ceramide significantly decreased EC proliferation at 15 µM 
compare to the control or 10 µM. Both C6-ceramide and GW4869 had no 
significant effects in the parental EC proliferation at 10 µM. This result further 
confirmed the effective concentration of 10 µM that allowed C6-
Ceramide/GW4869 regulates MV/EXM release without significant affects the 
parental ECs. 
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Fig 5. The effect of C6-Ceramide/GW4869 on EC proliferation. ECs were 
treated with C6-Ceramide at 0, 10, 15 µM or GW4869 at 0, 5, 10 µM for 24 
hours. Cell proliferation was tested by the MTT method and was calculated as 
fold changes in the treated groups versus the vehicle group. Data is 
presented as mean ± SEM, n=5/group, * P<0.01 versus Veh. Veh: Vehicle 
group; +C6-ceramide: cells treated with C6-Ceramide; +GW4869: cells 
treated with GW4869. 
 
 
C6-Ceramide but not GW4869 treatment increased miR-126 expression in 
ECs. 
To evaluate the effects of MV/EXM releasing regulation in EC function, the EC 
specific microRNA miR-126 expression in ECs was analyzed by qRT-PCR. 
GW4869 and C6-Ceramide treatment at a concentration of 10 µM had no effect 
on miR-126 expression in ECs compared to the control (Fig 6). However miR-
V
e
h
5
 μ
M
1
0
 μ
M
1
0
 μ
M
1
5
 μ
M
0 .0
0 .5
1 .0
1 .5
5  μ M
V e h
1 5  μ M
Veh 
+GW4869 
+C6-Ceramide 
C
e
ll 
p
ro
lif
e
ra
ti
o
n
 
 
(f
o
ld
 o
f 
c
o
n
tr
o
l)
 
* 
25 
126 expression in C6-Ceramide treated ECs was significantly different from 
GW4869 treated ECs (Fig 6). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6. Effect of modulating MV/EXM release via C6-ceramide and GW4869 on 
miR-126 expression in ECs. ECs were treated with C6-ceramide or GW4869 at 
10 µM for 24 hours. miR-126 expression of ECs in different treatment groups 
was analyzed by qRT-PCR. Data is presented as Mean ± SEM, n=3/group, # 
P<0.05 versus +GW4869. miR-126: microRNA-126; Veh: Vehicle group; +C6-
ceramide: cells treated with C6-Ceramide; +GW4869: cells treated with 
GW4869. 
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GW4869 increased the EC ability in EC-MV up-taking (merging). 
ECs release and uptake MVs and EXMs to transfer biological messages and 
communicate with other cells. The ability of particle uptake can also be 
considered as a factor that reflects ECs health and function. The particle uptake 
ability was measured by fluorescence microscopy. C6-Ceramide-/GW4869- 
treated ECs were co-incubated with PKH26 labeled normal EC-MVs for 24 
hours. Fluorescence images were taken every 3 hours for the measurement of 
red fluorescence. The images showed that particles merged into cells. After 24 
hours, the fluorescence images indicated that the labeled MVs had been 
uptaken by ECs (Fig 7A). The intensity changes of the red fluorescence images 
were considered to reflect the MV uptake ability of ECs. Figure 7 showed that 
under GW4869 treatment at 10 µM, the MV uptake rate of ECs largely 
increased compared to the control. C6-Ceramide had no effect on the EC MV 
uptake ability. 
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Fig 7. Modulating efect of MV/EXM release on the MV uptake ability of ECs. A) 
Representative PKH26 staining images of EC-MVs merged into ECs observed 
under microscope after treatments for 24 hours. Cells were treated with C6-
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Ceramide or GW4869 at 10 µM and PKH26 stained normal EC-MVs for 24 
hours. Fluorescence images were taken every 3 hours. B) Data summary for 
the intensity of red fluorescence from PKH26 labeled normal EC-MVs that 
merged into treated ECs. The intensity changes of the red fluorescence refer 
to the MV uptake ability of ECs under different treatments. n=3/group. Veh：
Vehicle group; +C6-ceramide: cells treated with C6-Ceramide ; +GW4869: cells 
treated with GW4869 . 
 
C6-Ceramide down-regulates miR-126 level in both EC-MVs and EC-EXMs, 
whereas GW4869 down-regulates miR-126 level in EC-EXMs, with no 
effect on EC-MVs. 
ECs were treated with C6-Ceramide or GW4869 at 10 µM for 24 hours. 
Released MVs and EXMs were collected from the culture medium. The level of 
miR-126 in MVs and EXMs was analyzed by qRT-PCR. The level of miR-126 
in both MVs and EXMs was decreased by C6-Ceramide treatment. GW4869 
treatment had also decreased miR-126 level in EXMs, but had no effect on MVs 
(Fig 8). 
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B) 
 
 
 
 
 
 
 
 
 
 
Fig 8. Effect of modulating MV/EXM release via C6-ceramide and GW4869 on 
miR-126 levels in EC-MVs and EC-EXMs. A) EC-MVs and B) EC-EXMs were 
isolated and the level of miR-126 in different treatment groups was analyzed by 
qRT-PCR. Data is presented as Mean ± SEM, n=3/group, *P<0.05, ** P<0.01 
versus Veh. miR-126: microRNA-126; Veh: Vehicle group; +C6-ceramide: cells 
treated with C6-Ceramide; +GW4869: cells treated with GW4869.  
 
EC-EXMs down-regulate Ang II stimulated SMC migration, but have no 
effect on normal SMC proliferation and migration. 
PKH26-labeled EX-MVs and EX-EXMs released from C6-Ceramide or 
GW4869 treatment were added to SMCs at 10 µg/ml. The fluorescence images 
showed that PKH26-labeled MVs/EXMs entered and accumulated into SMCs 
(Fig 9A), indicating that cultured SMCs communicate with co-incubated MVs 
and EXMs. Cell proliferation and migration of SMCs were analyzed to 
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30 
determine whether there were function alterations by EC-MVs and EC-EXMs. 
Cell proliferation was measured by the MTT method, and migration was tested 
by the wound healing method. EC-MVs and EC-EXMs released by C6-
Ceramide or GW4869 at a concentration of 10 µM had no effect on normal SMC 
proliferation and migration (Fig 10). Under Ang II stimulation (100 nM), EC-
EXMs released by both GW4869 and C6-Ceramide reduced SMC migration 
compared to the control. EC-MVs had no effect on Ang II stimulated SMC 
migration. 
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B) EC-MV treatment 
 
 
 
 
 
 
 
 
Fig 9. Effects of C6-Ceramide or GW4869 mediated EC-MVs and EC-EXMs in 
SMC proliferation. A) After incubation with EC-EXMs or B) EC-MVs for 24 hours, 
cell proliferation of SMCs was tested by the MTT method. Veh: Vehicle group; 
+C6-ceramide: MVs or EXMs released form cells treated with C6-Ceramide; 
+GW4869: MVs or EXMs released form cells treated with GW4869. 
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B）EC-EXMs treatment 
 
 
 
 
 
 
 
 
 
 
C) EC-MVs treatment 
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D)  
 
 
 
 
 
Fig 10. Effect of C6-Ceramide- or GW4869-mediated MVs or EXMs on SMC 
cell migration. A) Fluorescence images indicate that EC-MVs and EC-EXMs 
merged into SMCs after 24 hours. SMC were wounded by sterilized pipette tips 
to cause 1.0 to 1.5 cm wound area. After incubation with B) EC-EXMs or A) EC-
MVs C) Ang II with EC-MVs and EC-EXMs for 24 hours, the wound area was 
measured to evaluate migration of SMCs. Veh: Vehicle group; +C6-ceramide: 
EC-MVs/EXMs released by the C6-Ceramide group; +GW4869: EC-
MVs/EXMs released by the GW4869 group. 
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VI. DISCUSSION 
. 
MVs and EXMs are extracellular vesicles released from membranes. They 
carry biological information molecules form parent cells and transfer information 
to target cells. Given their properties to transfer messages, they could be used 
as a drug delivery tool for disease treatment, such as cardiovascular disease 
and cancer. This potential application has generated an increased interest in 
the budding and releasing mechanisms of MVs and EXMs. In this study, we 
choose a simple lipid mechanism of MV and EXM release, being the main 
component ceramide, which is also associated with MV release, to study EC-
MVs and EC-EXMs. 
 
The structure of ceramide influence vesicle formation. D-erythro-C6-ceramide 
(C6-Ceramide) is the most active ceramide analogue tested [35]. C6-ceramide 
has a dose dependent inhibitory effect on cell growth. Mouse fibroblast cells 
treated with C6-ceramide at 10 µM produce minor effects on cell growth, 
modest inhibition of cell growth at 15 µM, and totally block cell growth and 
significantly reduce cell viability at 20 µM [35]. Similar results were obtained in 
this study. Treatment with C6-ceramide at 10 µM had no significant effects on 
EC proliferation (Fig 5). At a concentration of 15 µM, cell proliferation was 
significantly affected (Fig 5). These results demonstrate the safety effective 
concentration of the drug. In addition, C6-Ceramide significantly induced EXMs  
 
35 
and MVs release at a concentration of 10 µM without affecting EC proliferation 
(Fig 4, 5). 
 
MVs and EXMs can transfer molecular messages form parent cells to recipient 
cells. miR-126 is a short non-coding microRNA which is highly expressed in 
endothelial cells. In this study, we detected the level of miR-126 in EC-MVs and 
EC- EXMs (Fig 8). The presence of miR-126 in EC-MVs and EC-EXMs further 
proved that MVs and EXMs derived from ECs transport their parent proteins 
and genetic materials. Previous studies showed that miR-126 is the most highly 
enriched microRNA in ECs [30]. It regulates several aspects of the EC biology, 
including cell migration, organization of the cytoskeleton, capillary network 
stability, and cell survival, demonstrating that miR-126 is required for the 
maintenance of vascular structure. It also plays an important role in 
angiogenesis. Angiogenic growth factors, such as vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF), regulate EC proliferation, 
migration and adhesion by activating the MAP kinase pathway, which 
culminates in the nucleus to enhance the expression of genes required for 
angiogenesis and vascular integrity. miR-126 can directly target the Sprouty-
related EVH1 domain-containing protein 1 (SPRED1) and phosphoinositol-3 
kinase regulatory subunit 2 (PIK3R2/p85-β), two negative regulators of the 
VEGF signaling pathway, to regulate angiogenesis [31].  
 
Considering the important vascular protective functions of miR-126, we 
evaluated the expression of miR-126 in ECs to determine the effects of 
modulating MV/EXM release by C6-ceramide and GW4869 in their parental EC 
36 
functions. However, results showed that both C6-Ceramide and GW4869 had 
no effect on miR-126 expression in ECs compare to the control （Fig 6）, but 
the expression in C6-ceramide-treated ECs was statistically significantly 
increased compared to its expression in GW4869-treated ECs (Fig 6). This 
finding indicates that the differences in miR-126 expression between C6-
ceramide- and GW4869-treated ECs may have altered EC function. To further 
study the causes of EC function changes upon modulation of particle release, 
we plan in future studies to perform additional EC functional tests such as 
measurement of NO production, eNOS expression and ROS production in 
parental ECs. Moreover, the changes in miR-126 level in EC-MVs and EC-
EXMs significantly decreased compared to the control (Fig 8). Considering the 
cardio-protective properties of miR-126, level changes in EC-MVs and EC-
EXMs may lead to a decrease in EC-MV or EC-EXM function. However, Ang II 
induced SMC migration was decreased by EC-EXMs (Fig 10D). Ang II is the 
main biologically active agent of the renin-angiotensin system. Several studies 
found that Ang II induces vascular SMC proliferation and migration, which is 
associated with various vascular pathological processes in cardiovascular 
diseases such as hypertension, atherosclerosis, and post-interventional 
restenosis [34, 36-38].  In this study, EC-EXMs inhibition of ang II-induced cell 
migration (Fig 10D) appears to uncover the vascular protective properties of 
EC-EXMs. The miR-126 level of EC-EXMs (Fig 8) may indicate that the 
protective function in Ang II induced SMC migration is independent of the miR-
126 level. Moreover, the effects of decreasing of miR-126 level in EC-MVs and 
EC-EXMs (Fig 8) and increasing in ECs still remain unclear. To further confirm 
the changes in C6-ceramide and GW4869 mediated EC-MVs and EC-XMs, 
37 
more experiments will be needed to test their functional content at the molecular 
level.     
 
Another interesting finding in this study is that GW4869 induced MV uptake by 
ECs (Fig 7). MVs can merged into target cells via phagocytosis or directly fusion 
into cells. This merging ability may vary due to the EC condition. The 
fluorescence images of PKH26 labeled EC-MVs co-incubated with ECs, 
showed that GW4869 induced MV uptake (Fig 7). This ability may refer to EC 
function. The increasing uptake level also may contribute to the study of MVs 
and EXMs as drug delivery factors. The mechanisms of MVs and EXMs 
merging to cells still remain unclear, and this is a new interesting subject for 
extracellular vesicle studies. The next steps regarding studies on the release 
mechanism of MVs and EXMs, will combine the release mechanism with the 
merging mechanism together to study EC-MVs and EC-EXMs more 
systematically. 
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VII. CONCLUSIONs 
 
Our data demonstrate that C6-Ceramide induces both MV and EXM release 
whereas GW4869 only decreases EXM release in ECs without affecting cell 
proliferation at the concentrations tested. In addition, the C6-Ceramide 
treatment increased miR-126 expression and GW4869 treatments increased 
MV uptake ability in ECs. EXMs inhibited Ang II-induced SMC migration with 
no effect on normal SMCs. In contrast, MVs released from ECs had no effect 
on Ang II-induced SMC migration. All these effects are independent of miR-126 
level in EXMs or MVs. The data suggest that because EXMs released under 
both stimulatory and inhibitory conditions had no effect on EC proliferation, 
these particles can be considered as vasoprotective. 
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